Back to School: How biopharma can reboot drug development. Access exclusive analysis here
TransTech said data from a Phase IIa trial in 128 Type II diabetics on stable doses of metformin showed that TTP399 significantly reduced HbA1c
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury